Shenzhen Hepalink Invests $13 Million in Canada's OncoQuest
November 24, 2015 at 04:28 AM EST
Shenzhen Hepalink Pharma closed a $13 million investment in OncoQuest, the oncology subsidiary of Canada's Quest PharmaTech Inc., giving Hepalink a 42% stake in OncoQuest. OncoQuest is developing several immunotherapeutic antibodies to treat cancer. The two companies are also reported to be in talks on a $5 million JV to develop OncoQuest's products in China. Hepalink is major global supplier of heparin API. More details.... Stock Symbols: (SHZ: 002399) (TSX-V: QPT) Share this with colleagues: // //